Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

March 24, 2021

Study Completion Date

March 24, 2021

Conditions
Pulmonary Fibrosis Due to COVID-19
Interventions
DRUG

Fuzheng Huayu Tablet

FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

DRUG

Vitamin C tablets

Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral;

DRUG

Placebo

Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

OTHER

respiratory function rehabilitation training

Health exercise, once a day

Trial Locations (1)

201203

Shuguang Hospital, Shanghai

All Listed Sponsors
collaborator

Hubei Hospital of Traditional Chinese Medicine

OTHER

collaborator

Jingmen No.1 People's Hospital

OTHER

collaborator

Wuhan No.1 Hospital

OTHER

collaborator

Wuhan Third Hospital

OTHER

collaborator

Huangshi Hospital of Traditional Chinese Medicine

UNKNOWN

lead

ShuGuang Hospital

OTHER

NCT04279197 - Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu | Biotech Hunter | Biotech Hunter